Press releases
- Charles River Laboratories Publishes 2023 Corporate Citizenship Report
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
- Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
- Charles River Laboratories to Present at Barclays Global Healthcare Conference
- Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing
- Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
- Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance
- Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test
- Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors
- Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call
More ▼
Key statistics
On Tuesday, Charles River Laboratories International Inc (CRL*:MEX) closed at 4,436.54, 13.48% below its 52-week high of 3,909.42, set on Dec 19, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 4,436.54 |
Average volume | 0.00 |
---|---|
Shares outstanding | 51.35m |
Free float | 50.38m |
P/E (TTM) | 29.19 |
Market cap | 13.83bn USD |
EPS (TTM) | 9.23 USD |
Data delayed at least 20 minutes, as of Dec 19 2023 11:30 GMT.
More ▼